Innovative treatment method called reflux therapy, developed by HK inno.N, enters the Indian market
In a significant development for the treatment of gastric reflux disease in India, Dr. Reddy's Laboratories and HK inno.N have announced the launch of P-CAB. This move marks the culmination of Dr. Reddy's commitment to delivering innovative treatment options in gastric reflux disease in India.
HK inno.N, a subsidiary of Kolmar Korea, debuted its gastroesophageal reflux disease treatment K-CAB in India under the brand name P-CAB 50 mg. The approval for K-CAB was granted in May, allowing it to be used for the treatment of erosive esophagitis, non-erosive reflux disease, and gastric ulcers in India.
K-CAB's entry into India, one of the world's leading pharmaceutical markets, has been met with enthusiasm. Kwak Dal-won, CEO of HK inno.N, expressed his pleasure at this development, noting that India ranks fourth in the world for the peptic ulcer drug market, following China, the US, and Japan.
Local sales and promotion of K-CAB in India are being handled by Dr. Reddy's Laboratories. M. V. Ramana, the CEO of Branded Markets (India and Emerging Markets) at Dr. Reddy's Laboratories, expressed the company's commitment to bringing forward new medicines that close treatment gaps and improve patient access in India.
The export agreement between HK inno.N and Dr. Reddy's Laboratories includes supplying K-CAB tablets to India and six other emerging countries. Under the Indian brand name P-CAB, K-CAB is expected to position itself as a globally recognised first-in-class therapy in the category, offering new treatment options to patients in India.
As of last year, India's peptic ulcer drug market was valued at around 1.52 trillion won ($1.1 billion). With the launch of P-CAB, Dr. Reddy's Laboratories plans to launch P-CAB 50mg in the local Indian market this month.
This partnership between Dr. Reddy's Laboratories and HK inno.N is set to revolutionise the treatment landscape for gastric reflux disease in India, providing patients with access to innovative and effective treatments in India.
Read also:
- Parliamentary Meetings in the Federal Diet of Germany this Week
- All individuals aged 75 and above to be incorporated in Respiratory Virus (RSV) prevention program, set to commence in September.
- Regulation Implementation Rules to be Established by the Commission for Enforcement Purposes
- Emergency services in Berlin are set to get a respite
